KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Long-Term Investments: 2013-2023

Historic Long-Term Investments for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Dec 2023 value amounting to $16.6 million.

  • Supernus Pharmaceuticals' Long-Term Investments fell 78.47% to $11.7 million in Q1 2024 from the same period last year, while for Mar 2024 it was $11.7 million, marking a year-over-year decrease of 78.47%. This contributed to the annual value of $16.6 million for FY2023, which is 82.30% down from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Long-Term Investments stood at $16.6 million for FY2023, which was down 82.30% from $93.9 million recorded in FY2022.
  • Supernus Pharmaceuticals' 5-year Long-Term Investments high stood at $591.8 million for FY2019, and its period low was $16.6 million during FY2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Long-Term Investments value was $93.9 million (recorded in 2022), while the average stood at $76.6 million.
  • In the last 5 years, Supernus Pharmaceuticals' Long-Term Investments spiked by 41.30% in 2019 and then slumped by 82.30% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Long-Term Investments (Yearly) stood at $591.8 million in 2019, then crashed by 40.80% to $350.4 million in 2020, then crashed by 65.99% to $119.2 million in 2021, then dropped by 21.21% to $93.9 million in 2022, then crashed by 82.30% to $16.6 million in 2023.